N-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide (BioDeep_00000173886)
human metabolite blood metabolite
代谢物信息卡片
N-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
化学式: C17H14Cl2F2N2O3 (402.0349)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 29.63%
分子结构信息
SMILES: C1CC1CON(C2=C(C=NC=C2Cl)Cl)C(=O)C3=CC=C(C=C3)OC(F)F
InChI: InChI=1S/C17H14Cl2F2N2O3/c18-13-7-22-8-14(19)15(13)23(25-9-10-1-2-10)16(24)11-3-5-12(6-4-11)26-17(20)21/h3-8,10,17H,1-2,9H2
描述信息
同义名列表
数据库引用编号
分类词条
相关代谢途径
Reactome()
BioCyc()
PlantCyc()
代谢反应
个相关的代谢反应过程信息。
Reactome()
BioCyc()
WikiPathways()
Plant Reactome()
INOH()
PlantCyc()
COVID-19 Disease Map()
PathBank()
PharmGKB()
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- S Vollert, N Kaessner, A Heuser, G Hanauer, A Dieckmann, D Knaack, H P Kley, R Beume, C Weiss-Haljiti. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.
Diabetologia.
2012 Oct; 55(10):2779-2788. doi:
10.1007/s00125-012-2632-z. [PMID: 22790061] - Yifei Zhong, Yingwei Wu, Ruijie Liu, Yueyi Deng, Sandeep K Mallipattu, Paul E Klotman, Peter Y Chuang, John C He. Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure.
Kidney international.
2012 May; 81(9):856-64. doi:
10.1038/ki.2011.467. [PMID: 22258322] - Patricio E Ray. Can we cure HIV-1-associated nephropathy in transgenic mice?.
Kidney international.
2012 May; 81(9):811-3. doi:
10.1038/ki.2012.13. [PMID: 22499139] - Norbert G Knebel, Rolf Herzog, Felix Reutter, Karl Zech. Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Apr; 893-894(?):82-91. doi:
10.1016/j.jchromb.2012.02.038. [PMID: 22425388] - Chung-Hung Shih, Ling-Hung Lin, Hsin-Te Hsu, Kuo-Hsien Wang, Chi-Yin Lai, Chien-Ming Chen, Wun-Chang Ko. Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia.
Evidence-based complementary and alternative medicine : eCAM.
2012; 2012(?):472897. doi:
10.1155/2012/472897. [PMID: 22454667] - Miki Kobayashi, Satoshi Kubo, Katsuhisa Shiraki, Masahiro Iwata, Yasuno Hirano, Yoshiaki Ohtsu, Koichiro Takahashi, Yasuaki Shimizu. Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation.
Pharmacology.
2012; 90(3-4):223-32. doi:
10.1159/000342380. [PMID: 23038661] - Thérèse Keravis, Fanny Monneaux, Issaka Yougbaré, Lucien Gazi, Jean-Jacques Bourguignon, Sylviane Muller, Claire Lugnier. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
PloS one.
2012; 7(1):e28899. doi:
10.1371/journal.pone.0028899. [PMID: 22247763] - You-Lan Yang, Hsin-Te Hsu, Kuo-Hsien Wang, Cheng-Ying Han, Chien-Ming Chen, Chi-Ming Chen, Wun-Chang Ko. Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.
Journal of biomedical science.
2011 Nov; 18(?):84. doi:
10.1186/1423-0127-18-84. [PMID: 22074248] - T D Bethke, M Hartmann, A Hünnemeyer, G Lahu, C H Gleiter. Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
International journal of clinical pharmacology and therapeutics.
2011 Aug; 49(8):491-9. doi:
10.5414/cp201556. [PMID: 21781649] - G Böhmer, C H Gleiter, A Hünnemeyer, G Lahu, T D Bethke. Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.
International journal of clinical pharmacology and therapeutics.
2011 Jul; 49(7):451-60. doi:
10.5414/cp201535. [PMID: 21726496] - N McCracken, G Lahu, T D Bethke. Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.
International journal of clinical pharmacology and therapeutics.
2011 Jun; 49(6):388-96. doi:
10.5414/cp201523. [PMID: 21612746] - Christian de Mey, Nassr Nassr, Gezim Lahu. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
BMC clinical pharmacology.
2011 Jun; 11(?):7. doi:
10.1186/1472-6904-11-7. [PMID: 21631929] - Gabriele M Böhmer, Christoph H Gleiter, Klaus Mörike, Nassr Nassr, Antje Walz, Gezim Lahu. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
Journal of clinical pharmacology.
2011 Apr; 51(4):594-602. doi:
10.1177/0091270010368282. [PMID: 20484614] - Wun-Chang Ko, Ling-Hung Lin, Hsin-Yi Shen, Chi-Yin Lai, Chien-Ming Chen, Chung-Hung Shih. Biochanin a, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness.
Evidence-based complementary and alternative medicine : eCAM.
2011; 2011(?):635058. doi:
10.1155/2011/635058. [PMID: 21437195] - Chung-Hung Shih, Tzu-Jung Huang, Chien-Ming Chen, Yun-Lian Lin, Wun-Chang Ko. S-Petasin, the Main Sesquiterpene of Petasites formosanus, Inhibits Phosphodiesterase Activity and Suppresses Ovalbumin-Induced Airway Hyperresponsiveness.
Evidence-based complementary and alternative medicine : eCAM.
2011; 2011(?):132374. doi:
10.1093/ecam/nep088. [PMID: 19641087] - T D Bethke, G Lahu. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast.
International journal of clinical pharmacology and therapeutics.
2011 Jan; 49(1):51-7. doi:
10.5414/cpp49051. [PMID: 21176727] - Karina Matthiesen, Jacob Nielsen. Cyclic AMP control measured in two compartments in HEK293 cells: phosphodiesterase K(M) is more important than phosphodiesterase localization.
PloS one.
2011; 6(9):e24392. doi:
10.1371/journal.pone.0024392. [PMID: 21931705] - Gezim Lahu, Andreas Hünnemeyer, Edgar Diletti, Martin Elmlinger, Peter Ruth, Karl Zech, Nigel McCracken, Axel Facius. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Clinical pharmacokinetics.
2010 Sep; 49(9):589-606. doi:
10.2165/11536600-000000000-00000. [PMID: 20690782] - Dave Singh, Frank Petavy, Alex J Macdonald, Aili L Lazaar, Brian J O'Connor. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.
Respiratory research.
2010 Mar; 11(?):26. doi:
10.1186/1465-9921-11-26. [PMID: 20193079] - Nassr Nassr, Andreas Huennemeyer, Rolf Herzog, Oliver von Richter, Robert Hermann, Manuela Koch, Kevin Duffy, Karl Zech, Gezim Lahu. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
British journal of clinical pharmacology.
2009 Oct; 68(4):580-7. doi:
10.1111/j.1365-2125.2009.03478.x. [PMID: 19843061] - J Cortijo, A Iranzo, X Milara, M Mata, M Cerdá-Nicolás, A Ruiz-Saurí, H Tenor, A Hatzelmann, E J Morcillo. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
British journal of pharmacology.
2009 Feb; 156(3):534-44. doi:
10.1111/j.1476-5381.2008.00041.x. [PMID: 19154443] - Roos C Padmos, Nanette C Schloot, Huriya Beyan, Cindy Ruwhof, Frank J T Staal, Dick de Ridder, Henk-Jan Aanstoot, Wai Kwan Lam-Tse, Harm de Wit, Christian de Herder, Roos C Drexhage, Barbara Menart, R David Leslie, Hemmo A Drexhage. Distinct monocyte gene-expression profiles in autoimmune diabetes.
Diabetes.
2008 Oct; 57(10):2768-73. doi:
10.2337/db08-0496. [PMID: 18599519] - Kathleen A Neville, Stanley J Szefler, Susan M Abdel-Rahman, Gezim Lahu, Karl Zech, Rolf Herzog, Thomas D Bethke, Melanie C Gleason, Gregory L Kearns. Single-dose pharmacokinetics of roflumilast in children and adolescents.
Journal of clinical pharmacology.
2008 Aug; 48(8):978-85. doi:
10.1177/0091270008319466. [PMID: 18508947] - Venkata R Narala, Rajesh Ranga, Monica R Smith, Aaron A Berlin, Theodore J Standiford, Nicholas W Lukacs, Raju C Reddy. Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma.
Respiratory research.
2007 Dec; 8(?):90. doi:
10.1186/1465-9921-8-90. [PMID: 18053220] - Robert Hermann, Werner Siegmund, Thomas Giessmann, Kristin Westphal, Anita Weinbrenner, Bernhard Hauns, Felix Reutter, Gezim Lahu, Karl Zech, Thomas D Bethke. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
Journal of clinical pharmacology.
2007 Aug; 47(8):1005-13. doi:
10.1177/0091270007300950. [PMID: 17660483] - Robert Hermann, Nassr Nassr, Gezim Lahu, Eva Péterfai, Dietrich Knoerzer, Rolf Herzog, Karl Zech, Christian de Mey. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
Clinical pharmacokinetics.
2007; 46(5):403-16. doi:
10.2165/00003088-200746050-00003. [PMID: 17465639] - Katsuya Kobayashi, Toshio Suda, Haruhiko Manabe, Ichiro Miki. Administration of PDE4 inhibitors suppressed the pannus-like inflammation by inhibition of cytokine production by macrophages and synovial fibroblast proliferation.
Mediators of inflammation.
2007; 2007(?):58901. doi:
10.1155/2007/58901. [PMID: 18274640] - Oliver von Richter, Gezim Lahu, Andreas Huennemeyer, Rolf Herzog, Karl Zech, Robert Hermann. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Clinical pharmacokinetics.
2007; 46(7):613-22. doi:
10.2165/00003088-200746070-00006. [PMID: 17596106] - T D Bethke, T Giessmann, K Westphal, A Weinbrenner, B Hauns, D Hauschke, M David, G Lahu, K Zech, R Hermann, W Siegmund. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
International journal of clinical pharmacology and therapeutics.
2006 Nov; 44(11):572-9. doi:
10.5414/cpp44572. [PMID: 17176624] - Kerryn McCluskie, Uwe Klein, Chris Linnevers, Yu-Hua Ji, Alfred Yang, Craig Husfeld, G Roger Thomas. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
The Journal of pharmacology and experimental therapeutics.
2006 Oct; 319(1):468-76. doi:
10.1124/jpet.106.105080. [PMID: 16861399] - Ellena J Growcott, Karen G Spink, Xiaohui Ren, Saliha Afzal, Kathy H Banner, John Wharton. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Respiratory research.
2006 Jan; 7(?):9. doi:
10.1186/1465-9921-7-9. [PMID: 16423283] - Zheng Huang, Joseph A Mancini. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.
Current medicinal chemistry.
2006; 13(27):3253-62. doi:
10.2174/092986706778773040. [PMID: 17168849] - Irfan Rahman. Antioxidant therapies in COPD.
International journal of chronic obstructive pulmonary disease.
2006; 1(1):15-29. doi:
10.2147/copd.2006.1.1.15. [PMID: 18046899] - Hyun Jeong Kwak, Jin Sook Song, Jun Young Heo, Sung Don Yang, Ji-Youn Nam, Hyae Gyeong Cheon. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
The Journal of pharmacology and experimental therapeutics.
2005 Dec; 315(3):1188-95. doi:
10.1124/jpet.105.092056. [PMID: 16126838] - Antonio Maurizio Vignola. PDE4 inhibitors in COPD--a more selective approach to treatment.
Respiratory medicine.
2004 Jun; 98(6):495-503. doi:
10.1016/j.rmed.2003.12.012. [PMID: 15191033] - Regina Draheim, Ute Egerland, Chris Rundfeldt. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
The Journal of pharmacology and experimental therapeutics.
2004 Feb; 308(2):555-63. doi:
10.1124/jpet.103.059097. [PMID: 14610230] - Eric S Muise, Ian C Chute, David Claveau, Paul Masson, Louise Boulet, Lydia Tkalec, Douglas J Pon, Yves Girard, Richard Frenette, Joseph A Mancini. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
Biochemical pharmacology.
2002 Apr; 63(8):1527-35. doi:
10.1016/s0006-2952(02)00903-6. [PMID: 11996895]
